OKYO Pharma announced that Chief Development Officer Gary Jacob acquired additional shares, reflecting ongoing confidence in the company's therapies.
Quiver AI Summary
OKYO Pharma Limited has announced that Chief Development Officer Gary Jacob has acquired an additional 30,980 shares of the company, increasing his total holdings to 108,920 shares. The company is focused on developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, with its lead drug, Urcosimod, showing promising results in clinical trials. Urcosimod, a peptide agonist, has demonstrated anti-inflammatory and pain-relieving effects in models of dry eye disease and NCP. Recently, OKYO reported positive outcomes from a Phase 2a trial with NCP patients and plans to initiate a Phase 2b/3 study involving approximately 150 subjects later this year. Further information is available on their website.
Potential Positives
- Gary Jacob, Chief Development Officer, has increased his personal stake in the company by acquiring 30,980 shares, indicating confidence in the company's future.
- OKYO has announced positive data from a Phase 2a trial that demonstrates significant pain reduction in patients with neuropathic corneal pain, supporting the efficacy of its lead drug, Urcosimod.
- The company is advancing its research and development efforts with plans to initiate a Phase 2b/3 multiple-dose study of Urcosimod, which signifies ongoing commitment to clinical advancement and potential market readiness.
- Urcosimod has shown promising results in earlier trials, which may strengthen its position in addressing both neuropathic corneal pain and dry eye disease, thereby expanding its therapeutic applicability.
Potential Negatives
- The press release emphasizes the financial commitment of the Chief Development Officer, which could raise concerns about insider trading or conflicts of interest, particularly if the stock price does not perform favorably.
- The ongoing clinical trials, while promising, also highlight the inherent risks of drug development, including the potential for failure in future phases and the associated financial implications for the company.
- OKYO's classification as a "clinical-stage" company implies that it has not yet brought a product to market, which may lead to investor wariness regarding its long-term viability and reliance on continued funding.
FAQ
What recent share acquisition was announced by OKYO Pharma?
Gary Jacob, Chief Development Officer, acquired 30,980 shares at $1.59, bringing his total to 108,920 shares.
What is Urcosimod used for?
Urcosimod is developed to treat neuropathic corneal pain (NCP) and inflammatory eye diseases.
What are the results of the Phase 2a trial for NCP?
The trial showed positive data on pain reduction in 18 subjects with neuropathic corneal pain.
What is the focus of OKYO Pharma?
OKYO Pharma focuses on developing innovative therapies for neuropathic corneal pain and ocular diseases.
What study is OKYO Pharma planning to initiate this year?
OKYO plans to initiate a Phase 2b/3 multiple-dose study of Urcosimod for NCP with approximately 150 subjects.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OKYO Hedge Fund Activity
We have seen 4 institutional investors add shares of $OKYO stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DAUNTLESS INVESTMENT GROUP, LLC removed 1,950,525 shares (-80.5%) from their portfolio in Q4 2025, for an estimated $4,037,586
- RENAISSANCE TECHNOLOGIES LLC added 96,800 shares (+235.0%) to their portfolio in Q4 2025, for an estimated $200,375
- NORTHERN TRUST CORP removed 57,158 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $118,317
- XTX TOPCO LTD added 17,612 shares (+inf%) to their portfolio in Q4 2025, for an estimated $36,456
- CITADEL ADVISORS LLC removed 15,355 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $31,784
- UBS GROUP AG added 2,172 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,496
- MORGAN STANLEY added 10 shares (+inf%) to their portfolio in Q4 2025, for an estimated $20
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OKYO Analyst Ratings
Wall Street analysts have issued reports on $OKYO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 02/20/2026
- HC Wainwright & Co. issued a "Buy" rating on 09/23/2025
To track analyst ratings and price targets for $OKYO, check out Quiver Quantitative's $OKYO forecast page.
$OKYO Price Targets
Multiple analysts have issued price targets for $OKYO recently. We have seen 3 analysts offer price targets for $OKYO in the last 6 months, with a median target of $7.0.
Here are some recent targets:
- Biren Amin from Piper Sandler set a target price of $7.0 on 02/20/2026
- William Woods from B. Riley Securities set a target price of $5.0 on 12/08/2025
- Yi Chen from HC Wainwright & Co. set a target price of $7.0 on 09/23/2025
Full Release
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company’s ordinary shares on NASDAQ at $1.59, bringing his total holding to 108,920 shares.
About Urcosimod (formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2a trial involving 18 neuropathic corneal pain subjects. Urcosimod has shown significant pain reduction in an earlier 240 subject Phase 2, multi-center, double-masked, placebo-controlled trial in DED, which supports the development rationale in NCP.
About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in subjects with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.
For further information, please visit www.okyopharma.com .
Inquiries:
| Business Development & Investor Relations | Paul Spencer |
+44 (0)20 7495 2379
|
